middle.news
How Will Dimerix’s New Data Shape FDA Approval for DMX-200?
8:43am on Wednesday 29th of October, 2025 AEDT
•
Healthcare
Read Story
How Will Dimerix’s New Data Shape FDA Approval for DMX-200?
8:43am on Wednesday 29th of October, 2025 AEDT
Key Points
259 patients enrolled in ACTION3 Phase 3 trial for DMX-200
Orphan Drug Designation granted in Japan, complementing US, Europe, UK
Positive PARASOL data analysis to support proteinuria endpoints
Strong cash position of AU$49.2 million with expected reduced trial spend
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE